Biotechnology
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock...
2022-12-14 23:47
2182
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1] which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamem® may assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2...
2022-12-14 21:52
1675
Circulating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs)with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at...
2022-12-14 21:00
1670
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...
2022-12-14 15:17
3919
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
GERMANTOWN, Md. and HONG KONG, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
2022-12-14 01:41
3638
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
GERMANTOWN, Md. and HONG KONG, Dec. 13, 2022 /PRNewswire/ -- Sirnaomics Ltd. ( the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in the discovery and development of advanced therapeutics centered around the messenger RNA ("mRNA"), announced today that its Ex...
2022-12-14 01:40
1961
Treadwell Therapeutics Announces A Presentation at the 2022 ASH Annual Meeting Featuring a Clinical Trial Update on CFI-400945, an oral PLK4 inhibitor
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, small molecule therapeutics for highly aggressive cancers, today announced a presentation for the Company's CFI-400945 program, a first in class inhibitor of Polo-like Kinase ...
2022-12-13 22:30
3483
VeriSIM Life Earns Frost & Sullivan Competitive Strategy Leadership Award for Best Practices in AI-enabled Preclinical Development Industry
VeriSIM Life eliminates waste and inaccuracy, accelerates preclinical development, and lowers costs and risks when converting drug candidates to clinical trials, and brings life-saving drugs to market faster. SAN ANTONIO, Dec. 13, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the artif...
2022-12-13 21:00
1683
Biosion Announces Research Collaboration with ImmunoGen to Create Novel Antibody-Drug Conjugates
Collaboration to explore potential of creating next-generation antibody-drug conjugateswith Biosion's SynTracer® internalization platform and ImmunoGen's proprietary linker-payload technology NEWARK, Del., Dec. 13, 2022 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global R&D biotechnology comp...
2022-12-13 18:00
1705
Live from ASH 2022 | Ascentage Pharma Presents Latest Data of APG-2575, Including Encouraging Results of the Combination with BTKi in Patients with R/R CLL/SLL
SUZHOU, China and ROCKVILLE, Md. , Dec. 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released preliminary results from a ...
2022-12-13 17:39
1644
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA
YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd.
2022-12-13 12:30
2004
CSL Announces Next CEO & Managing Director
Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from6 March 2023 MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed DrPaul McKenzie as Chief Executive Officer (CEO)...
2022-12-13 07:23
3178
Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19
--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects --Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data ...
2022-12-12 23:29
3620
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatat the 2022 American Society of Hematology (the "ASH") Annual Mee...
2022-12-12 21:50
2079
PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
DAEJEON, South Korea, Dec. 12, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co...
2022-12-12 21:00
1663
Asieris'Bladder Cancer Diagnostic Drug Hexvix® Completed Dosing of First Patient in Real-World Clinical Study
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix®, a drug used for bladder c...
2022-12-12 20:59
1520
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, presented the latest clinical data on Carteyva® (relmacabtagene autoleucel injection) in...
2022-12-12 18:00
4136
HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Dec. 11, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. ("Nitrase"), a biopharmaceutical company deploying its NITROME platform to buil...
2022-12-12 10:10
1739
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate
BCMA/CD19 dual-targeting FasTCAR-T GC012F data from ongoing clinical trial presented at 64th American Society of Hematology Annual Meeting and Exposition SAN DIEGO and SUZHOU and SHANGHAI, China, Dec. 10, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL)...
2022-12-11 07:15
3529
Goodwin Biotechnology Inc. is now GBI, as Part of their Rebranding Initiative on their 30-Year Anniversary!
PLANTATION, Fla., Dec. 10, 2022 /PRNewswire/ -- Goodwin Biotechnology, Inc. announces its new name, GBI, as part of a rebranding initiative to commemorate its 30-year anniversary. This includes a new name, logo and website to reflect its evolution from an early-stage clinical manufacturing Contra...
2022-12-10 04:16
2973
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 289 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21
Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 253 media titles]
2024-04-30 15:13Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
12716
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
8214
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
7746
